KCT0009298
Recruiting
未知
A 12-week, Randomized, Double-blind, Placebo-controlled Multi-center Study to Investigate the Efficacy and Safety of CKDB001 on Cognitive-enhancing Function
Chong Kun Dang Bio0 sites100 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Chong Kun Dang Bio
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Individuals who have voluntarily given written informed consent after receiving sufficient explanation about this human application trial.
- •2\) Adult men and women aged 55 to less than 80 years as of the date of written consent.
- •3\) Individuals who are capable of understanding Korean.
- •4\) Individuals whose score on the SVLT\-E of the SNSB\-II is decreased by more than 1\.0 SD but less than 2\.0 SD compared to the normal standard for the same education level and age group.
Exclusion Criteria
- •\- Individuals with any of the following medical histories or surgical/procedural histories: diseases accompanied by cognitive impairment, history of mental illness that may affect this human application trial, history of infections affecting brain function, severe concomitant diseases/disabilities deemed unsuitable for study participation by the researcher, etc.
- •\- Individuals who have taken the following drugs and food within 4 weeks of Visit 2 (Baseline): those who have been administered or are expected to be administered during the study period drugs that can affect cognitive function, those who have continuously consumed or are expected to consume health functional foods or dietary supplements related to cognitive and memory improvement, etc.
- •\- Individuals with hypersensitivity to any component of the test food or other allergies deemed unsuitable for study participation by the researcher's opinion.
- •\- Pregnant or breastfeeding women.
- •\- Women of childbearing potential and men who are unwilling or unable to use appropriate contraception methods during the study period.
- •\- Individuals who have participated in another study involving clinical trial drugs, foods, or medical devices within the past 3 months.
- •\- Any other reasons deemed by the researcher as inappropriate for conducting the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisEUCTR2017-002177-20-ATAllergan Ltd.311
Active, not recruiting
Phase 1
A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007, PT008 and placebo in asthma patients 4 years of age or older (DENALI).Symptomatic AsthmaMedDRA version: 21.0Level: LLTClassification code 10003561Term: Asthma, unspecifiedSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2018-003674-27-CZBond Avillion 2 Development LP1,000
Active, not recruiting
Phase 1
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisDiabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2017-002177-20-ROAllergan Ltd.311
Active, not recruiting
Phase 1
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisDiabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2017-002136-16-ITALLERGAN LIMITED2,500
Active, not recruiting
Phase 1
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisEUCTR2017-002177-20-HUAllergan Ltd.2,500